Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by SPCEO1on Mar 16, 2022 11:20am
112 Views
Post# 34518453

RE:RE:RE:New Corporate Presentation up

RE:RE:RE:New Corporate Presentation upI am guessing the dashed green boxes indicate the patients that recieved this dosage. So patient 1 passed away and I am guessing patient 3 did too. I am not sure why the patients 2,4 and 5 did not move to the 420 level - anyone know why they might not have advanced to this higher level - poor health perhaps? They took a quick dip from 420 to 360 to look at that as an option but evidently decided 300mg was the best. 

It would have been nice if they told us exactly where they are right now.  

SPCEO1 wrote: It seems like it refers to the 2nd footnote which says this is the currently available dose. But I am not 100% sure of that. Probably 95% sure but wonder if there are other theories out there.

SPCEO1 wrote: Anyone want to take a guess as to what the blue "2" means under the first patient at the 300mg level?

SPCEO1 wrote: https://www.theratech.com/static-files/ddb819a0-33ef-485d-aae8-d587b8cb36bf

I don't think it tells us anything we did not already know or presume but  have only had time to glance at it.

 




<< Previous
Bullboard Posts
Next >>